DekaBank Deutsche Girozentrale Purchases 1,375 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

DekaBank Deutsche Girozentrale raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 67,996 shares of the company’s stock after purchasing an additional 1,375 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Teva Pharmaceutical Industries were worth $688,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 184,642.3% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after buying an additional 27,696,340 shares during the last quarter. Sound Shore Management Inc CT bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $80,791,000. State Street Corp grew its stake in shares of Teva Pharmaceutical Industries by 29.4% during the first quarter. State Street Corp now owns 19,564,828 shares of the company’s stock worth $172,988,000 after buying an additional 4,441,883 shares during the last quarter. Exor Capital LLP grew its stake in shares of Teva Pharmaceutical Industries by 30.3% during the fourth quarter. Exor Capital LLP now owns 15,008,389 shares of the company’s stock worth $93,903,000 after buying an additional 3,486,202 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 14.4% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock worth $276,000,000 after buying an additional 3,413,100 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $13.23 on Tuesday. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. The stock has a market capitalization of $14.83 billion, a P/E ratio of -28.15, a price-to-earnings-growth ratio of 1.54 and a beta of 1.05. The firm’s fifty day simple moving average is $13.41 and its two-hundred day simple moving average is $11.17. Teva Pharmaceutical Industries Limited has a 12 month low of $7.09 and a 12 month high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. The business had revenue of $4.46 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Insider Activity

In other news, CAO Amir Weiss sold 31,766 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the transaction, the chief accounting officer now owns 10,676 shares in the company, valued at $132,062.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Eric Drape sold 9,815 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the transaction, the vice president now owns 9,701 shares in the company, valued at $127,277.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amir Weiss sold 31,766 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 390,738 shares of company stock worth $5,132,766. Company insiders own 0.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a research note on Friday, March 8th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. HSBC initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, December 18th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.